Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29114916 | 0.86 | LMNA (0.58) | LMNAKMT2AHPGDCD274KDM5B | |
| SCHEMBL20285004 | 0.83 | KDM5B (0.60) | LMNAKMT2AHPGDCD274KDM5B | |
| SCHEMBL12161407 | 0.81 | ALDH1A1 (0.59) | LMNAHPGDHTR2AMMP12PTGS2 | |
| SCHEMBL10643373 | 0.81 | HSD17B10 (0.55) | LMNAKMT2AHPGDCD274KDM5B | |
| SCHEMBL17883262 | 0.81 | HPGD (0.62) | LMNAKMT2AHPGDCD274KDM5B | |
| SCHEMBL29114948 | 0.80 | HTT (0.55) | LMNAKMT2ACD274HTR2AHTT | |
| SCHEMBL16373632 | 0.80 | LMNA (1.00) | LMNAKMT2AHPGDCD274HTT | |
| SCHEMBL17511039 | 0.78 | RAB9A (0.49) | KMT2AHIF1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7137369 | 0.78 | KDM5B (0.63) | LMNAKMT2AHPGDCD274KDM5B | |
| SCHEMBL10430969 | 0.77 | KMT2A (0.65) | LMNAKMT2AHPGDCD274KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738011-B2 | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738011-B2 | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180327363-A1 | DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2016105484-A1 | DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327363-A1 | DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | CFTR, SLC33A1, SLC26A4 | LMNA 3574/4885KMT2A 1675/4885HPGD 1648/4885 |
| US-10738011-B2 | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, SLC33A1, SLC26A4 | LMNA 3574/4885KMT2A 1675/4885HPGD 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.